Alican I

Baek KJ

Buster BL

Chartrain NA

Corbett JA

Dawson VL

Ding M

Fozard JR

Furfine ES

Garvey EP

Griscavage JM

Grover R

Guntupalli K

Hock CE

Iadecola C

Ignarro LJ

Kengatharan M

Klatt P

Kwon NS

Lancaster JR

Moncada S

Murad F

Nathan C

Pou S

Ridger VC

Schulz JB

Stadler J

Tsukahara H

Wagner DA

Wang J

Weinberg JB

 ▪ Abstract  Nitric oxide (NO) regulates numerous physiological processes, including neurotransmission, smooth muscle contractility, platelet reactivity, and the cytotoxic activity of immune cells. Because of the ubiquitous nature of NO, inappropriate release of this mediator has been linked to the pathogenesis of a number of disease states. This provides the rationale for the design of therapies that modulate NO concentrations selectively. A well-characterized family of compounds are the inhibitors of NO synthase, the enzyme responsible for the generation of NO; such agents are potentially beneficial in the treatment of conditions associated with an overproduction of NO, including septic shock, neurodegenerative disorders, and inflammation. This article provides an overview of NO synthase inhibitors, focusing on agents that prevent binding of substrate l-arginine. </jats:p

INHIBITION OF NITRIC OXIDE SYNTHASE AS A POTENTIAL THERAPEUTIC TARGET

Abstract

Similar works

Full text

Available Versions

Crossref